Generated by AI
Evolus Inc. is a performance beauty company focused on the cash-pay medical aesthetics market. Evolus Inc. markets Jeuveau, a proprietary neurotoxin used by licensed aesthetic practitioners for temporary improvement in the appearance of moderate to severe frown lines, and Evolysse, a collection of injectable hyaluronic acid gel products for facial aesthetic treatment. The company serves practitioners and consumers across the United States and selected international markets, including Canada, Europe, and Australia, with a business model centered on self-pay aesthetic procedures. Evolus Inc. positions its portfolio around non-reimbursed treatments, combining product commercialization, practitioner support, and brand-led marketing within the medical aesthetics industry.
Website520 Newport Center Drive
Newport Beach, CA, 92660
United States
The latest articles about EOLS.
Evolus Inc (EOLS) reaffirmed full-year revenue guidance of $330 million to $337 million while trimming operating expense outlook and advancing its injectable pipeline toward three launches by 2030.
Summary of May 5's posts. Generated by AI.
Summary of Mar 5's posts. Generated by AI.
Summary of Mar 4's posts. Generated by AI.
Summary of Mar 5's posts. Generated by AI.
Investors talking about EOLS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.